Eisai Co., Ltd. (ESAIY)
Eisai Co., Ltd. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Tokyo, TY, JP. The stock last traded at $7.81, up 0.51% on the session, giving a market capitalisation of $8.82B. On trailing twelve-month figures it carries a trailing P/E of 33.23, a net margin of 4.9%. Its beta of -0.07 implies it has historically moved less than the broad market.
Eisai Co., Ltd. is a Japanese pharmaceutical firm deeply involved in the entire lifecycle of drug development, from initial research and innovation to manufacturing, distribution, and international trade within Japan. Its comprehensive product portfolio includes prominent medications such as Dayvigo, prescribed for insomnia, and the potent anticancer drug Lenvima, a molecularly targeted therapy effective against thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma when paired with everolimus. The company also markets Methycobal for peripheral neuropathy and Halaven, another anticancer agent targeting breast cancer. Further offerings encompass Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid formulation; Goofice and Movicol, utilized for managing chronic constipation; Fycompa, an antiepileptic; Pariet, a proton-pump inhibitor; and Aricept, a treatment for Alzheimer's and Dementia with Lewy bodies. Additionally, it produces Chocola BB plus, a vitamin B2 supplement. Eisai maintains a strategic alliance with Bristol Myers Squibb, focusing on the joint development and commercialization of the antibody drug conjugate, farletuzumab ecteribulin. Established in Tokyo, Japan, in 1941, the company was initially known as Nihon Eisai Co., Ltd. before adopting its current name, Eisai Co., Ltd., in 1955.
Eisai Co., Ltd. is most often compared with the following Healthcare names: